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Interleukin 2 production by peripheral blood lymphocytes in allograft
recipients during acute rejection episodes. In this study we investigate
the relationship between the Interleukin 2 (IL-2) yield produced by
kidney allograft recipient's peripheral blood lymphocytes (PBL) under
lectin stimulation and the occurrence of acute rejection episodes. PBL
were harvested prospectively before grafting, after grafting in steady-
state period, and at the onset of acute rejection episodes. In addition,
we tested retrospectively the ability of PBL of recipients engrafted for
more than 1 yr to produce IL-2. IL-2 levels were assessed on the
IL-2-dependent CTL-L2 murine cell line. Our data show: I) before
grafting, hemodialysed patients (N = 14) produced normal IL-2 yield
compared with healthy donors (N = 21);2) the IL-2 secretion of PBL of
recipients with good graft function (N = 18) is decreased markedly
during roughly the first 12 months following transplantation (P < 0.01);
3) when acute rejection crisis occurred during this time period (N = 24),
a sharp and highly significant increment (P < 0.01) in lectin-induced
IL-2 production of recipient's PBL was seen. After 1 yr, the capacity to
secrete IL-2 upon lectin stimulation tends to be restored. Finally, our
data correlate rejection and high PBL-IL-2 secretion clearly at a time
when recipients with well-functioning grafts have markedly impaired
IL-2 secretion.
La production d'Interleukine 2 par des lymphocytes sanguins périph.
ériques de receveurs d'allogreffe au cours d'épisodes de rejet aigu. Nous
avons étudié Ia relation entre Ia production d'Interleukine 2 (IL-2) par
des lymphocytes sanguins périphériques (PBL) de receveurs d'al-
logreffe rénale lors d'une stimulation par une lectine, et lors de la
survenue d'un episode de rejet aigu. Les PBL étaient recueillis
prospectivement avant Ia greffe, après la greffe lors d'un episode de
stabilitC, et au maximum des episodes de rejet aigu. En outre, nous
avons testé rétrospectivement Ia capacité des PBL des donneurs greffés
depuis plus d'un an a produire de l'IL-2. Nos données montrent: 1)
qu'avant la greffe, les hémodialysés (N = 14) produisaient une IL-2
normale par rapport a des. donneurs sains (N = 21); 2) que Ia sécrétion
d'IL-2 par les PBL de receveurs dont Ia fonction du greffon était bonne(N = 18) diminuait de facon marquee au cours des 12 premiers mois
apres Ia transplantation (P < 0.01); 3) et que lorsqu'une crise de rejet
aigu se produisait pendant cette période (N = 24), ii existait une
augmentation prononcée et trés significative (P < 0.01) de Ia production
d'IL-2 lectine-induite par les PBL des receveurs. Au bout d'une année,
la capacité de sécréter de l'IL-2 lors d'une stimulation par une lectine
tendait a Ctre restaurée. Enfin, nos données établissent clairement une
correlation entre le rejet ella sécrétion élevée de PBL-IL-2 lorsque les
receveurs dont les greffons fonctionnent bien ont une sécrétion d'IL-2
trés altérée.
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Interleukin 2 (IL-2) is a 15 KD glycoprotein [1] produced
mainly by helper T cells [2] under antigen and monokine [3]
stimulation. Antigen or lectin-activated T lymphocytes acquire
a surface membrane receptor for IL-2 (RIL-2), and the IL-2-
RIL-2 interaction induces T cell mitosis [4]. Since IL-2 is
required for the expansion of activated T lymphocytes, it is
probably involved in the cellular process leading to graft
rejection that occurs after host lymphocyte activation by donor
antigens. Although lymphocytes infiltrating the rejected al-
lograft are the ultimate effector cells [5], peripheral blood
lymphocytes (PBL) can recognize antigen and may be cytotoxic
to donor target cells [6], therefore giving information on im-
mune events linked to graft rejection. Moreover, PBL of the
helper phenotype have been shown to transfer rejection capac-
ity [7], suggesting that lymphokine-secreting cells—and there-
fore lymphocytes per se—may play an important role in trig-
gering rejection.
This study investigated the ability of PBL from kidney
transplant recipients to produce IL-2 when stimulated in vitro
by mitogens. Blood samples were drawn prospectively from
patients immediately before grafting, at various times after
grafting when in a steady-state condition, and immediately
before treatment of unambiguous acute rejection episodes. PBL
harvested before grafting were found to produce normal levels
of IL-2, while PBL of grafted recipients with stable renal
function yielded low levels of IL-2. In contrast, rejecting
recipients' PBL produced very high levels of IL-2 when stim-
ulated by lectin.
Methods
Prospective study
Twenty-five patients engrafted for less than 12 months were
studied (the period when 88% of the acute rejection episodes
occurred), 23 first cadaveric and 2 living-related graft recipi-
ents. Twenty-one healthy individuals served as controls. Blood
samples were systematically drawn before transplantation and
at various times after grafting when patients showed good renal
function. In addition, samples were obtained prospectively in
all recipients who underwent an obvious acute rejection crisis
(N = 24) at the very time of diagnosis and before any treatment
of the episode. Rejection treatment consisted of anti-
lymphocyte globulin (ALG) (Institut Merieux, Lyon, France)
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for seven days with 1 mg/kg/day of prednisone (CS) for the first
week, tapered to 15 mg/day by decreasing the CS doses by 10
mg per week. The rejection episodes were diagnosed on the
basis of increased blood creatinine (>50 /Lmole/liter), graft
enlargement and local tenderness in the absence of any alter-
native diagnosis. Samples obtained from patients with episodes
of renal failure that could not be clearly attributed to rejection,
for example, infectious or toxic episodes, were discarded.
All patients were systematically transfused before and at the
time of grafting as described previously [8]. All received horse
ALG for the first 2 weeks following transplantation at a dose
required to keep their SRBC-T rosetting PBL between 5 and
15%. Blood samples were not drawn during ALG treatment to
avoid the specific effect of ALG. Prednisone was given at 1
mg/kg/day for 2 weeks after grafting and tapered to 20 mg/day at
the end of the second month. Azathioprine (AZA) was admin-
istered at 2 to 3 mg/kg, according to the white blood cell count.
After the second month, ten recipients received cyclosporin A
(5 to 6 mg/kg/day) with no additional immunosuppressive
agents, according to a randomized trial comparing CS alone to
a conventional regimen, specifically CS + AZA.
Rejecting or steady-state patients received non-statistically
different doses of steroids at the time of bleeding, 22 16 vs. 18
24 mg/day, respectively.
Retrospective study
To assess IL-2 production by PBL of recipients with long-
term, well-functioning grafts, 18 blood samples of recipients
engrafted for a period ranging from 1 to 10 years were obtained.
All recipients were under conventional CS + AZA treatment.
Culture medium and lymphocytes
Culture medium (CM) was RPM! 1640 (GIBCO) supple-
mented with 10% agammaglobulinemic human serum (CTS,
Lille, France) and gentamicin (10 g/ml). PBL were obtained
from heparinized blood by sedimentation on Ficoll-hypaque,
washed twice, and frozen in liquid nitrogen until used. Subse-
quently, PBL were checked routinely for viability (>90%
required), and adjusted at the concentration required for the
following tests.
IL-2 production
Optimal parameters (concentration of cells/mi, PHA dose,
culture vessels, serum concentration and kinetics of IL-2 pro-
duction) allowing reproducible IL-2 production of lectin-
stimulated cells were assessed before starting the experiments
and led to the following method: PBL were cultured in 96 well
tissue culture plates (Nunc, Roskilde, Denmark) (0.2 ml/well) at
4. 10 ml1 in 0.1 ml of CM supplemented with 0.5% v/v PHA-P
(Difco, Glasgow, Scotland). Cultures were set up in duplicate,
and 48 hr later 75 d of supernatant were harvested from each
well, pooled, and kept at 4°C until assayed for IL-2.
IL-2 assay
The amount of IL-2 contained in the supernatant of PHA-
stimulated PBL was assayed on the CTL-L2 IL-2-dependent
cell line. Briefly, CTL-L2 (5000 per well) were incubated in
Nunc tissue culture microplates (0.2 mI/well) in the presence of
log 2 dilutions of either a reference IL-2-source containing 1
U/mI of IL-2 or supernatants of PHA-stimulated PBL of con-
trols and patients. The same IL-2 standard containing 1 U/mI
according to Bertoglio et al [9) was tested along with superna-
tants in all experiments, allowing the comparison between the
various titers of IL-2 obtained. After 48 hr of culture, 0.25 Ci
3(H)TdR (Amersham, United Kingdom; SA 23 Ci/mM) was
added to each well. The cells were harvested 4 hr later with a
Skatron multisample harvester and counted for radioactivity.
Results are given in units of IL-2/ml, as defined previously [9],
as well as in the average amount of 3(H)TdR incorporated by
CTL-L2 (expressed as cpm) in the presence of the PBL
supernatants at each of the dilutions tested (1/4 to 1/128).
Statistical analysis
The absolute values of 3(H)TdR incorporation in CPM ob-
tained after CTL-L2 incubation with the supernatants at serial
log 2 dilutions were compared, using the Student and Wilcoxon
tests. When the values could be paired (pre-graft and various
post-graft values obtained from PBL of an individual in the
same experiment), comparisons were made using the paired
Student's t test.
Results
Lectin-induced IL-2 production of PBL of healthy individuals
and pre-graft (hemodialyzed) patients
Figure 1 shows the IL-2 yield under standard conditions in 21
normal healthy donors and 14 hemodialyzed patients before
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Fig. 1. IL-2 yields of PHA -stimulated PBL from patients tested before
grafting (A, N = 14) and from healthy individuals (•, N = 21).
(Difference not significant).
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grafting. The average amount of IL-2 produced did not differ
significantly.
Lectin-induced IL-2 production of kidney allograft recipients
Twenty-four clearly individualized rejection episodes were
studied and compared with control individuals and non-
rejecting kidney-graft recipients, as well as with homologous
pre-graft values. A highly significant (P < 0.01) difference was
noted in the lectin-induced IL-2 yields (assessed either by
comparison of the cpm obtained from CTL-L2 stimulated by
the tested supematants or by comparison of the U/mi of IL-2
produced; data not shown). Indeed, although PBL of all recip-
ients taken as a single group produced significantly lower IL-2
levels than those of either healthy controls (P < 0.01) or an
homologous sample taken before grafting (P < 0.01), PBL of
recipients who were acutely rejecting their graft produced
significantly more (P <0.01) IL-2 than those of recipients with
non-rejecting grafts studied at equivalent time periods after
grafting (Fig. 2). It is important to point out that the average
intake of CS and AZA did not differ between clinically stable
patients and those rejecting their grafts, since blood samples
were taken before treatment for the rejection. Ten patients
taking cyclosporin A were tested for PHA-induced IL-2 pro-
duction during a period of stable graft function. They produced
amounts of IL-2 similar to those of recipients treated with CS
and AZA who also had good graft function; therefore, the
Fig. 3. IL-2 production of recipients' PBL harvested serially at various
times: A, before grafting; B, steady-state; C, at the onset of an acute
rejection. All samples tested in a same experiment. *3H TdR incorpo-
ration of CTL-L2 cultured in PHA-induced conditioned medium tested
at 1:4 dilution. P < 0.05 between A and C and between B and C values
(Wilcoxon paired test).
values concerning both these types of steady-state recipients
were pooled.
Furthermore, serial blood samples covering the steady-state
and rejection periods were studied in some patients. In these
instances, care was taken to test the various samples of the
same patient in the same experiments. Again, the IL-2 pro-
duced by PBL harvested at these different times showed a
significantly sharp increase at the time of rejection (Fig. 3) (P <
0.05, paired t test).
IL-2 production in long-term kidney graft recipients
Although the PHA-stimulated PBL of the above recipients
yielded low IL-2, note that they were all studied within a year
following transplantation. To determine whether the low IL-2
production was permanent, patients, all of whom had good graft
function, were tested at further intervals, >1 year. Figure 4
indicates that, interestingly, PBL of such long-term recipients
with well-functioning grafts were capable of producing nearly
normal amounts of IL-2 when stimulated by PHA under stan-
dard conditions, thus showing that the IL-2 production of
kidney recipients tends to be restored with time.
Discussion
Our data show: 1) there is a normal IL-2 yield from
hemodialyzed patients' PBL; 2) the capacity for IL-2 secretion
of PBL of recipients with good graft function is grossly impaired
during the first 12 months following transplantation; 3) when a
rejection crisis occurred during this time period, there was a
sharp and highly significant increment in lectin-induced IL-2
production of recipient's PBL; 4) in long-term, well-functioning
graft recipients (>2 years), the capacity of PBL to secrete IL-2
upon lectin stimulation tends to be restored.
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Fig. 2. IL-2 yields of PHA -stimulated PBL of recipients tested either in
a steady-state period (A, N = 8) or at the time of an acute rejection
episode (N, N = 24) (P < 0.01).
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Fig. 4. Time restoration of IL-2 production capacity of kidney recipi-
ents' PBL. Values (X SD) of patients tested at 1, 1 to 3 months (N =
19); 2, 3 to 12 months (N = 18); 3, 1 to 2 years (N = 11); and 4 after 2
years (N = 12). Values obtained in healthy individuals (N = 21) are
given in 5. *Same as Fig. 3.
The very low IL-2 secretion by PHA-stimulated PBL of
kidney recipients after grafting contrasts with the normal IL-2
production capacity of PBL of these patients harvested imme-
diately before grafting and suggests that immunosuppressive
therapy (CS and AZA) is involved. CS are known to impair the
IL-2 production of lymphocytes in vitro dramatically [10];
however, PBL of non-grafted patients, for example, those with
systemic lupus erythematosus treated with CS, do not exhibit
lower IL-2 production [11]. Moreover, it would seem that
prolonged CS treatment can result in "escape" from the IL-2
secretion blockade. Caution is required, therefore, if one indi-
cates that CS alone is responsible in this IL-2-secretion defect
after transplantation. AZA may be involved also, although this
possibility has yet to be studied in vitro or in vivo. Other
explanations for the low IL-2 level in the supernatants of
PHA-stimulated PBL of these recipients may involve adaptive
regulation of immune function, for example, suppressor cells.
In addition, the relationship of impaired endogeneous produc-
tion of IL-2 to a decrease in NK cells that bear IL-2 receptors
[121 perhaps should be addressed since it has been shown that
natural killer (NK) effector functions are decreased dramati-
cally in the first year following an allograft also [131.
The patients with acute rejection episode produced high
levels of IL-2 compared to those of non-rejecting recipients (P
< 0.01), although at the time of testing the average level of
immunosuppressive drug intake was similar in both groups. In
several cases, serial blood samples were collected before rejec-
tion, at the time of rejection, and several weeks after rejection
(data not shown). These data confirmed that high IL-2 produc-
tion occurred only at the very time of the rejection episode.
This increase in IL-2 level associated with rejection may be
due either to an increase in the T lymphocytes able to secrete
IL-2 under activation (T4, primarily) or to an increase of the
IL-2 production by a given activated lymphocyte at the time of
rejection (laboratory analysis in progress). In addition, it is not
clear whether the increased IL-2 production is the cause or the
effect of rejection, and samples must be drawn systematically at
close intervals after transplantation to determine the answer.
Although the absence of a radioimmunoassay for IL-2 makes it
difficult to monitor the IL-2 level in the blood, the recognition of
an association between high PBL capacity to produce IL-2 after
PHA activation and graft rejection may bring new possibilities
of monitoring recipient immune responses in the near future.
Our data do not clarify the possible role of this increased IL-2
production by PBL in triggering or in sustaining the cellular
events underlying rejection. Increased IL-2 production may
only reflect, at the peripheral level, the increase of activated
T4 cells, which has been shown in animal models to transfer
rejection capacity in immuno-incompetent allograft recipients
[7]. However, it is likely that these cells are activated by the
allogeneic stimuli within the graft. In this case, they may play a
role in recruiting and amplifying the cellular immune response
against the graft [5], since recent findings have shown an IL-2
requirement for allograft rejection in rodents [14].
The interpretation of the data is complicated by the observa-
tion that the PBL capacity of IL-2 production is not decreased
in recipients with good renal function years after grafting. It
may be hypothesized that, at that time, adaptive mechanisms
such as anti-idiotypic antibodies [15, 161 and specific suppressor
cells [171 inhibit (at the anti-donor clonal level) the specific
response against graft antigens. On the other hand, IL-2 secre-
tion may be restored years after transplantation simply because
of a reduction in immunosuppressnt dose. Finally, although
further studies are still required to clarify the predictive values
as well as the relevance of high IL-2 production by PBL in the
mechanism of rejection, our data correlate rejection and high
PBL IL-2-secretion clearly at a time when recipients with
well-functioning grafts have markedly impaired secretion of this
lymphokine.
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